VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Impact in
- Oncology 347
- Immunology 315
Classified as
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm.4308 →Countries where authors are citing VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
This map shows the geographic impact of VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer more than expected).
Fields of papers citing VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
This network shows the impact of VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
About VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
This paper, published in 2017, received 475 indexed citations . Written by Jianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Z. Shi, Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jianfeng Chen, Hong Chen and Eleni Efstathiou covering the research area of Oncology, Immunology and Pulmonary and Respiratory Medicine. It is primarily cited by scholars working on Oncology (347 citations), Immunology (315 citations), Pulmonary and Respiratory Medicine (82 citations), Molecular Biology (43 citations) and Cancer Research (21 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm.4308.